Form 4: Mirum Pharmaceuticals CFO Reports Stock Transactions
SEC Form 4 Filing
Eric Bjerkholt, CFO of Mirum Pharmaceuticals, reports the vesting and disposal of restricted stock units.
Summary
- On January 23, 2025, Eric Bjerkholt, the Chief Financial Officer of Mirum Pharmaceuticals, engaged in transactions involving the company's stock.
- He disposed of 2,667 shares of common stock.
- These transactions involved the vesting of restricted stock units, each representing a contingent right to receive one share of common stock.
- Following the reported transactions, Bjerkholt directly owns 35,946 shares of common stock and 5,333 restricted stock units.
Sentiment
Score: 5
Explanation: This is a neutral report of stock transactions, with no inherent positive or negative sentiment.
Industry Context
This is a routine disclosure of stock transactions by a company insider, as required by SEC regulations. It doesn't necessarily indicate a change in the company's prospects or management's confidence.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but it's unlikely to be significant.
Key Dates
| Date | Description |
|---|---|
| 01/23/2024 | Vesting Commencement Date for restricted stock units |
| 01/23/2025 | Date of stock transactions (disposal of shares and vesting of restricted stock units) |
| 01/27/2025 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.